SCHEMBL13609688

SCHEMBL13609688

CC(C)CCCNC(=O)CCCC[C@@H]1SCC2NC(=O)N[C@@H]21

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 5/20 0.73
▸ CAPN1 P07384 2/20 0.62
▸ MEN1 O00255 1/20 0.60
▸ ABL1 P00519 1/20 0.60
▸ LMNA P02545 1/20 0.60
▸ PKM P14618 1/20 0.60
▸ IDE P14735 1/20 0.60
▸ MAPK1 P28482 1/20 0.60
▸ KMT2A Q03164 1/20 0.60
▸ RIN1 Q13671 1/20 0.60
▸ L3MBTL1 Q9Y468 1/20 0.60
▸ CA12 O43570 2/20 0.59
▸ CA1 P00915 2/20 0.59
▸ CA2 P00918 2/20 0.59
▸ CA9 Q16790 2/20 0.59
▸ FOLH1 Q04609 2/20 0.57
▸ F2 P00734 1/20 0.56
▸ PRSS1 P07477 1/20 0.56
▸ PRSS2 P07478 1/20 0.56
▸ PRSS3 P35030 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24067575 0.98 TDP1 (0.76) TDP1CAPN1MEN1ABL1LMNA
SCHEMBL14570855 0.97 TDP1 (0.74) TDP1CAPN1MEN1ABL1LMNA
SCHEMBL12352865 0.94 TDP1 (0.71) TDP1CAPN1MEN1ABL1LMNA
SCHEMBL20369791 0.94 TDP1 (0.71) TDP1CAPN1MEN1ABL1LMNA
SCHEMBL19543512 0.94 TDP1 (0.71) TDP1CAPN1MEN1ABL1LMNA
SCHEMBL13367527 0.89 TDP1 (0.80) TDP1CAPN1MEN1ABL1LMNA
SCHEMBL14523052 0.89 TDP1 (0.70) TDP1CAPN1MEN1ABL1LMNA
SCHEMBL26210081 0.89 F2 (0.66) TDP1CAPN1MEN1ABL1LMNA
SCHEMBL18779801 0.89 TDP1 (0.78) TDP1CAPN1MEN1ABL1LMNA
SCHEMBL9412852 0.89 TDP1 (0.74) TDP1MEN1ABL1LMNAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622289-B2 Ornithine aminotransferase (OAT): a target for anticancer drugs BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2009-11-24 — — US disclosed
US-20070287679-A1 Ornithine aminotransferase (OAT): a target for anticancer drugs BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2007-12-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287679-A1 Ornithine aminotransferase (OAT): a target for anticancer drugs OAT, OTC, GOT1 TDP1 655/4885CAPN1 1673/4885MEN1 3036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback